<DOC>
	<DOCNO>NCT02977533</DOCNO>
	<brief_summary>Primary Objective : To assess safety tolerability GZ402668 single subcutaneous ( SC ) dose men woman progressive multiple sclerosis . Secondary Objectives : To assess men woman progressive multiple sclerosis : - The pharmacokinetic ( PK ) parameter GZ402668 single SC dose . - The pharmacodynamic ( PD ) response GZ402668 single SC dose .</brief_summary>
	<brief_title>A Single Ascending Dose Study GZ402668 Patients With Progressive Multiple Sclerosis</brief_title>
	<detailed_description>The total study duration screen patient approximately 8 week . Upon completion trial , patient treat GZ402668 require enroll 4 year safety follow-up study continue safety observation .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Inclusion criterion : Male female adult diagnosis progressive multiple sclerosis ( MS ) include primary progressive MS , secondary progressive MS , progressive relapsing MS . Aged 18 65 year , inclusive . Body weight great 40.0 kg . Female patient child bear potential must use 2 highly effective contraception method . Male patient , whose partner childbearing potential ( include lactate woman ) , must accept use , sexual intercourse , 2 highly effective contraception method . Males patient , whose partner pregnant , must use , sexual intercourse , condom inclusion 4 month investigational medicinal product administration . Males patient agree donate sperm 4 month product administration . Exclusion criterion : Significant medical disease condition , include poorly control hypertension , cardiovascular disease , inflammatory disorder , immunodeficiency , autoimmune disease , renal failure , liver dysfunction , cancer ( except treat basal skin cell carcinoma ) , active infection . Frequent headache and/or migraine , recurrent nausea and/or vomit . History presence drug alcohol abuse . Smoking 5 cigarette equivalent per day . If female , pregnancy , lactating , breastfeed . Patients relapsingremitting MS . Treatment natalizumab , methotrexate , azathioprine , cyclosporine past 6 month . Treatment mitoxantrone , cyclophosphamide , cladribine , rituximab immunosuppressant cytotoxic therapy ( steroid ) last 12 month , determine treat physician residual immune suppression treatment . Treatment glatiramer acetate interferon beta past 4 week . Treatment fingolimod within past 2 month . Treatment dimethyl fumarate past 4 week . Treatment teriflunomide within past 12 month unless patient complete accelerated clearance cholestyramine . Previous treatment alemtuzumab . Live , attenuate vaccine within 3 month prior randomization visit , varicellazoster , oral polio , rubella vaccine . Clinically significant abnormality thyroid function . Inability undergo magnetic resonance image gadolinium administration . Hypersensitivity contraindication acyclovir . Known bleed disorder . Significant autoimmune disease . Active infection high risk infection . Latent active tuberculosis . Major psychiatric disorder adequately control treatment . Epileptic seizure adequately control treatment . Prior history invasive fungal infection . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>